Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Aug;100(8):2129-2131.
doi: 10.1007/s00277-021-04442-x. Epub 2021 Feb 2.

Management of chronic patients during the COVID-19 pandemic: the experience of a referral center for rare hematological disorders in the hardest-hit region in Italy

Irene Motta  1   2 , Alessia Marcon  3   4 , Maria Domenica Carrabba  3 , Elena Cassinerio  3 , Margherita Migone De Amicis  3 , Adriana Branchi  3   4 , Marianna Giuditta  5 , Diletta Maira  3 , Giovanna Fabio  3 , Giovanna Graziadei #  3 , Marina Baldini #  3
Affiliations

Management of chronic patients during the COVID-19 pandemic: the experience of a referral center for rare hematological disorders in the hardest-hit region in Italy

Irene Motta et al. Ann Hematol. 2021 Aug.
No abstract available

PubMed Disclaimer

Conflict of interest statement

IM received lecture honoraria from Sanofi-Genzyme and is member of Sanofi-Genzyme and Amicus Therapeutics advisory board. AM, MDC, EC, MMDA, AB, MG, DM, GF, GG, MB declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Impact of the COVID-19 pandemic on treatment management during the first wave (March–May 2020) and second wave (September–December). Treatments were overall regularly administered. Hereby, we report all the TDT, GD1, and AIDs followed in our center and their respective treatments. Moreover, we report only the SCD, S/THAL, Fabry disease, CVID, and XLA which require regular transfusional/infusional therapy (*). Few patients missed the therapy, mainly by choice. One patient with Fabry disease switched from IV enzyme replacement therapy to oral chaperon treatment (§). Noteworthy, despite the pandemic, new diagnosis have been made and new treatments have started (#). During the second wave, a higher number of patients had a symptomatic form of SARS-Cov-2 infection compared to the first wave, consistent with the general population epidemiology. IV, intravenous; COVID-19, coronavirus disease; TDT, transfusion-dependent thalassemia; SCD, sickle cell disease; S/THAL, sickle/thalassemia; GD1, Gaucher disease type 1; ERT, enzyme replacement therapy; CVID, common variable immunodeficiency; XLA, X-linked agammaglobulinemia; AIDs, autoinflammatory diseases; SCIG, subcutaneous immunoglobulin; NA, not applicable
See this image and copyright information in PMC

References

    1. Grasselli G, Pesenti A, Cecconi M. Critical care utilization for the COVID-19 outbreak in Lombardy, Italy: early experience and forecast during an emergency response. JAMA. 2020;323(16):1545–1546. doi: 10.1001/jama.2020.4031. - DOI - PubMed
    1. Auxilia F, Maraschini A, Bono P, et al. COVID-19: new scenario old problems. Acta Biomed. 2020;91(Suplement9):90–91. doi: 10.23750/abm.v91i2-S.10119. - DOI - PMC - PubMed
    1. Motta I, Migone De Amicis M, Pinto VM, et al. SARS-CoV-2 infection in beta thalassemia: preliminary data from the Italian experience. Am J Hematol. 2020;95(8):E198–E199. doi: 10.1002/ajh.25840.. - DOI - PMC - PubMed